Componenti:
Metodo di azione:
Opzione di trattamento:
Revisione medica di Oliinyk Elizabeth Ivanovna, Pharmacy Ultimo aggiornamento in data 16.03.2022
Attenzione! Le informazioni sulla pagina sono solo per gli operatori sanitari! Le informazioni sono raccolte in fonti pubbliche e possono contenere errori significativi! Fare attenzione e ricontrollare tutte le informazioni da questa pagina!
Primi 20 medicinali con gli stessi componenti:
Tazicef allo stato secco deve essere conservato tra 20 ° e 25 ° C (68 ° a 77 ° F) e protetto da luce. Tazicef (ceftazidime per iniezione, USP) è una polvere secca, da bianca a biancastra fornito in flaconcini come segue :
Flaconcini: equivalente a 1 grammo e 2 grammi di ceftazidime.
1 grammo (tradimento di 25) : NDC 0409-5082-16
2 grammi (tradimento di 10) : NDC 0409-5084-11
Disponibile anche come:
Flaconcini per pacchetti in blocco della farmacia : equivalente a 6 grammi di ceftazidime.
6 grammi (tradimento di 10): NDC 0409-5086-11
Flaconcini ADD-Vantage®: equivalente a 1 grammo e 2 grammi di ceftazidime.
1 grammo: NDC 0409-5092-16
2 grammi : NDC 0409-5093-11
Prodotto da Sandoz GmbH per: Hospira Worldwide, Inc., Lake Forest, IL 60045, USA., Made in Kundl, Austria. Revisionato: ottobre 2014
Tazicef (ceftazidime for injection, USP) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases:
- Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains).
- Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci).
- Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli.
- Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillinsusceptible strains).
- Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains).
- Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli.
- Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant).
- Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae.
Tazicef (ceftazidime for injection, USP) may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used.
Tazicef may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin and clindamycin; in severe and life-threatening infections, and in the immuno-compromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. The dose depends on the severity of the infection and the patient's condition.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tazicef (ceftazidime) and other antibacterial drugs, Tazicef (ceftazidime) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Dosage
The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8 to 12 hours. The dosage and route should be determined by the susceptibility of the causative organisms, the severity of infection, and the condition and renal function of the patient.
The guidelines for dosage of Tazicef (ceftazidime for injection, USP) are listed in Table 5. The following dosage schedule is recommended.
Table 5: Recommended Dosage Schedule
Dose | Frequency | |
Adults Usual recommended dosage | 1 gram IV or IM | q8-12hr |
Uncomplicated urinary tract infections | 250 mg IV or IM | q12hr |
Bone and joint infections | 2 grams IV | q12hr |
Complicated urinary tract infections | 500 mg IV or IM | q8-12hr |
Uncomplicated pneumonia; mild skin and skin-structure infections | 500 mg to 1 gram IV or IM | q8hr |
Serious gynecologic and intra-abdominal infections | 2 grams IV | q8hr |
Meningitis | 2 grams IV | q8hr |
Very severe life-threatening infections, especially in immunocompromised patients | 2 grams IV | q8hr |
Lung infections caused by Pseudomonas spp. in patients with cystic fibrosis with normal renal function* | 30 to 50 mg/kg IV to a maximum of 6 grams per day | q8hr |
Neonates (0 - 4 weeks) | 30 mg/kg IV | q12hr |
Infants and children (1 month - 12 years) | 30 to 50 mg/kg IV to a maximum of 6 grams per day† | q8hr |
* Although clinical improvement has been shown,
bacteriologic cures cannot be expected in patients with chronic respiratory
disease and cystic fibrosis. † The higher dose should be reserved for immunocompromised pediatric patients or pediatric patients with cystic fibrosis or meningitis. |
Impaired Hepatic Function
No adjustment in dosage is required for patients with hepatic dysfunction.
Impaired Renal Function
Ceftazidime is excreted by the kidneys, almost exclusively by glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration rate [GFR] < 50 mL/min), it is recommended that the dosage of ceftazidime be reduced to compensate for its slower excretion. In patients with suspected renal insufficiency, an initial loading dose of 1 gram of ceftazidime may be given. An estimate of GFR should be made to determine the appropriate maintenance dosage. The recommended dosage is presented in Table 6.
Table 6: Recommended Maintenance Dosages of Tazicef (ceftazidime
for injection, USP) in Renal Insufficiency
Creatinine Clearance (mL/min) | Recommended Unit Dose of Tazicef | Frequency of Dosing |
50 to 31 | 1 gram | q12hr |
30 to 16 | 1 gram | q24hr |
15 to 6 | 500 mg | q24hr |
< 5 | 500 mg | q48hr |
NOTE: IF THE DOSE RECOMMENDED IN TABLE 5 ABOVE IS LOWER THAN THAT RECOMMENDED FOR PATIENTS WITH RENAL INSUFFICIENCY AS OUTLINED IN TABLE 6, THE LOWER DOSE SHOULD BE USED.
When only serum creatinine is available, the following formula (Cockcroft's equation)4 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function:
Males: | (weight in kg) x (140 – age) |
(72) x serum creatinine (mg/100 mL) | |
Females | (0.85) x (above value) |
In patients with severe infections who would normally receive 6 grams of Tazicef daily were it not for renal insufficiency, the unit dose given in the table above may be increased by 50% or the dosing frequency may be increased appropriately. Further dosing should be determined by therapeutic monitoring, severity of the infection, and susceptibility of the causative organism.
In pediatric patients as for adults, the creatinine clearance should be adjusted for body surface area or lean body mass, and the dosing frequency should be reduced in cases of renal insufficiency.
In patients undergoing hemodialysis, a loading dose of 1 gram is recommended, followed by 1 gram after each hemodialysis period.
Tazicef (ceftazidime for injection, USP) can also be used in patients undergoing intraperitoneal dialysis and continuous ambulatory peritoneal dialysis. In such patients, a loading dose of 1 gram of Tazicef may be given, followed by 500 mg every 24 hours. In addition to IV use, Tazicef can be incorporated in the dialysis fluid at a concentration of 250 mg for 2 L of dialysis fluid.
Note: Generally Tazicef should be continued for 2 days after the signs and symptoms of infection have disappeared, but in complicated infections longer therapy may be required.
Administration
Tazicef may be given intravenously or by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh. Intra-arterial administration should be avoided (see PRECAUTIONS).
Intramuscular Administration
For IM administration, Tazicef should be reconstituted with one of the following diluents: Sterile Water for Injection, Bacteriostatic Water for Injection, or 0.5% or 1% Lidocaine Hydrochloride Injection. Refer to Table 7.
Intravenous Administration
The IV route is preferable for patients with bacterial septicemia, bacterial meningitis, peritonitis, or other severe or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or pending.
For direct intermittent IV administration, reconstitute Tazicef as directed in Table 7 with Sterile Water for Injection. Slowly inject directly into the vein over a period of 3 to 5 minutes or give through the tubing of an administration set while the patient is also receiving one of the compatible IV fluids (see Compatibility And Stability).
For IV infusion, reconstitute the 1-gram or 2-gram vial and add an appropriate quantity of the resulting solution to an IV container with one of the compatible IV fluids listed under the COMPATIBILITY AND STABILITY section.
Intermittent intravenous infusion with a Y-type administration set can be accomplished with compatible solutions. However, during infusion of a solution containing ceftazidime, it is desirable to discontinue the other solution.
Table 7: Preparation of Solutions of Tazicef
Vial Size | Amount of Diluent to Be Added | Approximate Available Volume | Approximate Ceftazidime Concentration |
Intramuscular | |||
1 gram | 3.0 mL | 3.6 mL | 280 mg/mL |
Intravenous Infusion | |||
1 gram | 10 mL | 10.6 mL | 95 mg/mL |
2 gram | 10 mL | 11.2 mL | 180 mg/mL |
All vials of Tazicef as supplied are under reduced pressure. When Tazicef is dissolved, carbon dioxide is released and a positive pressure develops.
Solutions of Tazicef, like those of most beta-lactam antibiotics, should not be added to solutions of aminoglycoside antibiotics because of potential interaction.
However, if concurrent therapy with Tazicef and an aminoglycoside is indicated, each of these antibiotics can be administered separately to the same patient.
Compatibility And Stability
Intramuscular
Tazicef (ceftazidime for injection, USP) when reconstituted as directed with Sterile Water for Injection, Bacteriostatic Water for Injection, or 0.5% or 1% Lidocaine Hydrochloride Injection, maintains satisfactory potency for 24 hours at room temperature or for 7 days under refrigeration. Solutions in Sterile Water for Injection that are frozen immediately after reconstitution in the original container are stable for 3 months when stored at -20°C. Once thawed, solutions should not be refrozen. Thawed solutions may be stored for up to 8 hours at room temperature or for 4 days in a refrigerator.
Intravenous
Tazicef (ceftazidime for injection, USP) when reconstituted as directed with Sterile Water for Injection, maintains satisfactory potency for 24 hours at room temperature or for 7 days under refrigeration. Solutions in Sterile Water for Injection in the original container or in 0.9% Sodium Chloride Injection in VIAFLEX® small-volume containers that are frozen immediately after reconstitution are stable for 6 months when stored at -20°C. Do not force thaw by immersion in water baths or by microwave irradiation. Once thawed, solutions should not be refrozen. Thawed solutions may be stored for up to 24 hours at room temperature or for 7 days in a refrigerator. More concentrated solutions in Sterile Water for Injection in the original container that are frozen immediately after constitution are stable for 3 months when stored at -20°C. Once thawed, solutions should not be refrozen. Thawed solutions may be stored for up to 8 hours at room temperature or for 4 days in a refrigerator.
Tazicef is compatible with the more commonly used IV infusion fluids. Solutions at concentrations between 1 mg/mL and 40 mg/mL in 0.9% Sodium Chloride Injection; 1/6 M Sodium Lactate Injection; 5% Dextrose Injection; 5% Dextrose and 0.225% Sodium Chloride Injection; 5% Dextrose and 0.45% Sodium Chloride Injection; 5% Dextrose and 0.9% Sodium Chloride Injection; 10% Dextrose Injection; Ringer's Injection, USP; Lactated Ringer's Injection, USP; 10% Invert Sugar in Water for Injection; and NORMOSOL®-M in 5% Dextrose Injection may be stored for up to 24 hours at room temperature or for 7 days if refrigerated.
Tazicef is less stable in Sodium Bicarbonate Injection than in other IV fluids. It is not recommended as a diluent. Solutions of Tazicef in 5% Dextrose Injection and 0.9% Sodium Chloride Injection are stable for at least 6 hours at room temperature in plastic tubing, drip chambers and volume control devices of common IV infusion sets.
Ceftazidime at a concentration of 4 mg/mL has been found compatible for 24 hours at room temperature for 7 days under refrigeration in 0.9% Sodium Chloride Injection or 5% Dextrose Injection when admixed with: cefuroxime (ZINACEF®) 3 mg/mL, heparin 10 U/mL or 50 U/mL or potassium chloride 10 or 40 mEq/L.
Vancomycin solution exhibits a physical incompatibility when mixed with a number of drugs, including ceftazidime. The likelihood of precipitation with ceftazidime is dependent on the concentrations of vancomycin and ceftazidime present. It is therefore recommended, when both drugs are to be administered by intermittent IV infusion, that they be given separately, flushing the IV lines (with 1 of the compatible IV fluids) between the administration of these 2 agents.
Note: Parenteral drug products should be inspected visually for particulate matter before administration whenever solution and container permit. As with other cephalosporins, Tazicef powder, as well as solutions, tend to darken depending on storage conditions; within the stated recommendations, however, product potency is not adversely affected.
WARNINGS
BEFORE THERAPY WITH TAZICEF IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFTAZIDIME, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS- HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO TAZICEF OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including ceftazidime, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. Elevated levels of ceftazidime in patients with renal insufficiency can lead to seizures, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia (see PRECAUTIONS).
PRECAUTIONS
General
High and prolonged serum ceftazidime concentrations can occur from usual dosages in patients with transient or persistent reduction of urinary output because of renal insufficiency. The total daily dosage should be reduced when ceftazidime is administered to patients with renal insufficiency (see DOSAGE AND ADMINISTRATION). Elevated levels of ceftazidime in these patients can lead to seizures, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia. Continued dosage should be determined by degree of renal impairment, severity of infection and susceptibility of the causative organisms.
As with other antibiotics, prolonged use of Tazicef (ceftazidime for injection, USP) may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patient's condition is essential.
If superinfection occurs during therapy, appropriate measures should be taken.
Inducible type I beta-lactamase resistance has been noted with some organisms (e.g., Enterobacter spp., Pseudomonas spp., and Serratia spp.). As with other extended-spectrum beta-lactam antibiotics, resistance can develop during therapy, leading to clinical failure in some cases.
When treating infections caused by these organisms, periodic susceptibility testing should be performed when clinically appropriate. If patients fail to respond to monotherapy, an aminoglycoside or similar agent should be considered.
Cephalosporins may be associated with a fall in prothrombin activity. Those at risk include patients with renal and hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated.
Tazicef should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Distal necrosis can occur after inadvertent intra-arterial administration of ceftazidime.
Prescribing Tazicef (ceftazidime) in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Carcinogenesis, Mutagenesis, Impairment Of Fertility
Long-term studies in animals have not been performed to evaluate carcinogenic potential. However, a mouse micronucleus test and an Ames test were both negative for mutagenic effects.
Pregnancy
Teratogenic Effects
Pregnancy Category B. Reproduction studies have been performed in mice and rats at doses up to 40 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to TAZICEF. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Nursing Mothers
Ceftazidime is excreted in human milk in low concentrations. Caution should be exercised when TAZICEF is administered to a nursing woman.
Pediatric Use
(see DOSAGE AND ADMINISTRATION).
Geriatric Use
Of the 2,221 subjects who received ceftazidime in 11 clinical studies, 824 (37%) were 65 and older while 391 (18%) were 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater susceptibility of some older individuals to drug effects cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION).
Effetti teratogeni
Gravidanza Categoria B Gli studi sulla riproduzione hanno. è stato eseguito su topi e ratti a dosi fino a 40 volte la dose umana e hanno non ha rivelato alcuna evidenza di ridotta fertilità o danno al feto a causa di TAZICEF Non esistono, tuttavia, studi adeguati e ben controllati su donne in gravidanza. Perché gli studi sulla riproduzione animale non sono sempre predittivi dell'uomo risposta, questo farmaco deve essere usato durante la gravidanza solo se chiaramente necessario.
Ceftazidime è generalmente ben tollerato. L'incidenza di le reazioni avverse associate alla somministrazione di ceftazidime erano basse studi clinici. Le più comuni sono state le reazioni locali a seguito di iniezione endovenosa e reazioni allergiche e gastrointestinali. Altre reazioni avverse sono state incontrato di rado. Non sono state riportate reazioni simili al disulfiram.
I seguenti effetti avversi degli studi clinici sono stati considerati correlati alla terapia con ceftazidime o erano incerti eziologia:
Effetti locali, riportato in meno del 2% di pazienti, erano flebite e infiammazione nel sito di iniezione (1 su 69 pazienti).
Reazioni di ipersensibilità , riportato nel 2% di i pazienti erano prurito, eruzione cutanea e febbre. Reazioni immediate, in generale manifestato da eruzione cutanea e / o prurito, si è verificato in 1 su 285 pazienti. Tossico necrolisi epidermica, sindrome di Stevens-Johnson ed eritema multiforme hanno è stato anche riportato con antibiotici cefalosporinici, incluso ceftazidime. Sono stati segnalati angioedema e anafilassi (broncospasmo e / o ipotensione) molto raramente.
Sintomi gastrointestinali, riportato in meno di Il 2% dei pazienti era diarrea (1 su 78), nausea (1 su 156), vomito (1 su 500) , e dolore addominale (1 su 416). L'insorgenza di sintomi di colite pseudomembranosa può verificarsi durante o dopo il trattamento (vedere AVVERTENZE).
Reazioni centrali al sistema nervoso (meno dell'1%) incluso mal di testa, vertigini e parestesia. Sono stati segnalati sequestri con diverse cefalosporine, incluso il ceftazidime. Inoltre, l'encefalopatia sono stati segnalati coma, asterixis, eccitabilità neuromuscolare e mioclonia in pazienti con insufficienza renale trattati con regimi posologici non aggiustati di ceftazidime (vedi PRECAUZIONI: Generale).
Eventi avversi meno frequenti (meno dell'1%) lo erano candidosi (incluso mughetto orale) e vaginite.
Ematologico
Sono stati segnalati rari casi di anemia emolitica.
Cambiamenti nei test di laboratorio notato durante la clinica le prove con Tazicef (ceftazidime per iniezione, USP) erano transitorie e incluso: eosinofilia (1 su 13), test Coombs positivo senza emolisi (1 in 23), trombocitosi (1 su 45) e lievi elevazioni in uno o più dei enzimi epatici, aspartato aminotransferasi (AST, SGOT) (1 su 16), alanina aminotransferasi (ALT, SGPT) (1 su 15), LDH (1 su 18), GGT (1 su 19) e fosfatasi alcalina (1 su 23). Come con alcune altre cefalosporine, elevazioni transitorie di urea ematica, azoto ureico nel sangue e / o creatinina sierica sono stati osservati occasionalmente. Leucopenia transitoria, neutropenia, agranulocitosi, trombocitopenia e la linfocitosi è stata osservata molto raramente.
Esperienza post-marketing con Tazicef (ceftazidime per iniezione, USP) Prodotti
Oltre agli eventi avversi segnalati durante studi clinici, i seguenti eventi sono stati osservati durante la clinica pratica in pazienti trattati con Tazicef e segnalati spontaneamente. Per alcuni di questi eventi, i dati non sono sufficienti per consentire una stima dell'incidenza o per stabilire la causalità.
Generale
Anafilassi; reazioni allergiche che, in raro casi, erano gravi (ad es., arresto cardiopolmonare); orticaria; dolore a sito di iniezione.
Tratto epatobiliare
Iperbilirubinemia, ittero.
Renal e genito-urinario
Insufficienza renale.
Reazioni avverse di classe cefalosporina
Oltre alle reazioni avverse sopra elencate sono stati osservati in pazienti trattati con ceftazidime, il seguente avverso reazioni e alterate prove di laboratorio sono state riportate per la classe cefalosporina antibiotici:
Reazioni avverse
Colite, nefropatia tossica, disfunzione epatica inclusa colestasi, anemia aplastica, emorragia.
Test di laboratorio alterati
Tempo di protrombina prolungato, test falso positivo per glucosio urinario, pancitopenia.
Il sovradosaggio di ceftazidime si è verificato in pazienti con insufficienza renale. Le reazioni hanno incluso attività convulsiva, encefalopatia asterixis, eccitabilità neuromuscolare e coma. Pazienti che ricevono un sovradosaggio acuto deve essere attentamente osservato e sottoposto a trattamento di supporto. In presenza di insufficienza renale, emodialisi o dialisi peritoneale possono aiutare nella rimozione di ceftazidime dal corpo.